Boston Scientific Co. (NYSE:BSX) Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC boosted its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 5.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,845,805 shares of the medical equipment provider's stock after buying an additional 96,451 shares during the quarter. Natixis Advisors LLC owned 0.13% of Boston Scientific worth $154,678,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Koshinski Asset Management Inc. acquired a new stake in shares of Boston Scientific in the first quarter valued at $250,000. Kingsview Wealth Management LLC lifted its position in shares of Boston Scientific by 4.1% during the first quarter. Kingsview Wealth Management LLC now owns 5,570 shares of the medical equipment provider's stock worth $381,000 after purchasing an additional 219 shares in the last quarter. Blair William & Co. IL lifted its position in shares of Boston Scientific by 9.3% during the first quarter. Blair William & Co. IL now owns 18,312 shares of the medical equipment provider's stock worth $1,254,000 after purchasing an additional 1,560 shares in the last quarter. Nwam LLC purchased a new position in shares of Boston Scientific in the first quarter valued at approximately $229,000. Finally, First Foundation Advisors acquired a new position in shares of Boston Scientific in the first quarter valued at approximately $25,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the company's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total value of $585,594.38. Following the sale, the executive vice president now owns 34,748 shares of the company's stock, valued at $2,913,967.28. This represents a 16.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael F. Mahoney sold 162,777 shares of the firm's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the transaction, the chief executive officer now directly owns 1,572,096 shares of the company's stock, valued at approximately $133,046,484.48. This trade represents a 9.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 309,270 shares of company stock valued at $26,196,718 in the last ninety days. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

Shares of BSX stock traded down $0.60 during trading hours on Friday, reaching $86.99. 10,230,145 shares of the company's stock were exchanged, compared to its average volume of 6,083,564. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. Boston Scientific Co. has a 1 year low of $53.56 and a 1 year high of $89.30. The company has a market cap of $128.21 billion, a P/E ratio of 71.88, a price-to-earnings-growth ratio of 2.61 and a beta of 0.79. The company's 50 day moving average is $85.26 and its two-hundred day moving average is $79.49.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. The company had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. Boston Scientific's quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.50 earnings per share. Equities research analysts anticipate that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Analysts Set New Price Targets

BSX has been the subject of several recent research reports. Stifel Nicolaus raised their price target on shares of Boston Scientific from $85.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, October 18th. Sanford C. Bernstein boosted their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an "outperform" rating in a research note on Thursday, October 24th. Morgan Stanley lifted their price objective on Boston Scientific from $92.00 to $100.00 and gave the company an "overweight" rating in a research note on Thursday, October 24th. Bank of America raised their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, October 22nd. Finally, Truist Financial boosted their price target on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Four investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $93.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.